Considering a Clinical Trial? Phase II Clinical Study of Lenvatinib

Eisai announced today the initiation of a global Phase III Clinical Study (Study 307, CLEAR Study) of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate (lenvatinib) in respective combination regimens with the anticancer agent everolimus and the anti-PD-1 antibody pembrolizumab as a potential first-line treatment for advanced renal cell carcinoma.06/17/2017
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news